Home Crystal structure of (E)-7-methoxy-2-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)methylene)-3,4-dihydronaphthalen-1(2H)-one, C22H25N3O2
Article Open Access

Crystal structure of (E)-7-methoxy-2-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)methylene)-3,4-dihydronaphthalen-1(2H)-one, C22H25N3O2

  • Wen-Wen Li , Yu Chen , Gui-Ge Hou ORCID logo and Feng Zhao EMAIL logo
Published/Copyright: July 31, 2025
Download Article (PDF)
Become an author with De Gruyter Brill
Submit Manuscript Author Information
Zeitschrift für Kristallographie - New Crystal Structures
From the journal Zeitschrift für Kristallographie - New Crystal Structures Volume 240 Issue 5

Abstract

C22H25N3O2, triclinic, P21 (no. 4), a = 11.0885(2) Å, b = 5.9571(1) Å, c = 14.7361(3) Å, β = 99.633(2)°, V = 959.67(3) Å3, Z = 2, R gt (F) = 0.0506, wR ref (F2) = 0.1503, T = 293 K.

CCDC no.: 2473121

The molecular structure is shown in the figure. Table 1 contains the crystallographic data and the list of the atoms including atomic coordinates and displacement parameters can be found in the cif-file attached to this article.

Table 1:

Data collection and handling.

Crystal: Clear light yellow block
Size: 0.16 × 0.14 × 0.12 mm
Wavelength: CuKα radiation (1.54178 Å)
μ: 0.65 mm−1
Diffractometer, scan mode: Rigaku Synergy, ω scan
θmax, completeness: 74.0°, 99 %
N(hkl)measured, N(hkl)unique, Rint: 5458, 3037, 0.013
Criterion for Iobs, N(hkl)gt: Iobs > 2σ(Iobs), 2,942
N(param)refined: 246
Programs: Bruker, 1 SHELX 2 , 3

1 Source of material

Synthesis method based on literature reports. 4 , 5 In a 500 mL spherical backside flask, (N)-methylpiperazine (16.03 g, 0.16 mol) and potassium carbonate (27.64 g, 0.2 mol) were reacted with N,N-dimethylformamide (20.0 mL) at 313 K for 12 h. Then 5-fluoropicolinaldehyde (1.76 g, 0.01 mol) is added to the system and the temperature is raised to 393 K for reflux reaction. Thin-Layer Chromatography (TLC, dichloromethane:methyl alcohol = 25:1, v:v) was used for detection, the reaction was stopped after 7 h. After cooling to room temperature, perform solid-liquid separation and wash the precipitate with dichloromethane (25.0 mL) until it turns white. After drying the solid, use a mixture of dichloromethane and methanol (50:1, v:v) as the eluent for purification by silica gel column chromatography to obtain the intermediate 5-(4-methylpiperazin-1-yl)picolinaldehyde. The intermediate (2.04 g, 0.01 mol) and 7-methoxy-3,4 dihydronaphthalen-1(2H)-one (1.76 g, 0.01 mol) were dissolved in methanol (15.0 mL), and 25 % NaOH (10.0 mL) was added as a catalyst. The reaction was carried out at room temperature for 5 h. The product was obtained by filtration under suction, washing the precipitate with 20 % methanol, followed by recrystallization with 10 mL of dichloromethane/methanol solution (1:1, v:v) to yield yellow crystals of the title compound.

2 Experimental details

The H atoms were placed in idealized positions and treated as riding on their parent atoms, with d(C–H) = 0.96 Å (methyl), Uiso(H) = 1.5 Ueq(C), and d(C–H) = 0.97 Å (methylene), Uiso(H) = 1.2 Ueq(C), and d(C–H) = 0.93 Å (aromatic), Uiso(H) = 1.2 Ueq(C).

3 Comment

3,4–Dihydronaphthalen-1(2H)-one derivatives 4 have been reported in numerous articles. Their key active fragment is the α, β-unsaturated ketone moiety, which is considered as a novel anti-inflammatory modulator. 5 It can inhibit COX-2 (cyclooxygenase-2) or regulate the NF- κ B pathway to reduce the release of inflammatory factors (such as IL-6 and TNF-α), 6 and also exhibits antibacterial and anti-tumor activities. 7 3,4–Dihydronaphthalen-1(2H)-one derivatives can bind to P65 and NLRP3 proteins. Molecular docking revealed that the naphthoquinone could fit well into the active pocket. 8 Research has found that nitrogen-containing heterocyclic compounds conjugated with naphthone can form hydrogen bonds with amino acid residues near the active site, further stabilizing the complex conformation and effectively inhibiting the release of inflammatory factors. 8 (N)-Methylpiperazine is primarily used as an important chemical intermediate in the pharmaceutical and chemical industries. Its derivatives have shown potential value in antibiotic, antipsychotic drug development, and anti-tumor research. 9 Therefore, introducing (N)-methylpiperazine and electron-withdrawing groups into the synthesis is expected to further enhance the activity of 3,4-dihydronaphthalen-1(2H)-one derivatives. We synthesized the target compound by starting with (N)-methylpiperazine and 5-fluoropicolinaldehyde as raw materials. Through a nucleophilic substitution reaction, we obtained the intermediate, which was then subjected to a Claisen–Schmidt reaction with 7-methoxy-3,4-dihydronaphthalen-1(2H)-one.

Single-crystal structure analysis reveals that there is only a molecule in the asymmetric unit of the title crystal structure (cf. the figure). 3,4-Dihydronaphthalen-1(2H)-one is the main pharmacophore, followed by the introduction of 5-(4-methylpiperazin-1-yl)picolinaldehyde at position 2 to form an α, β-unsaturated ketone. The bond lengths of C(1)=O(1), N(1)=C(12), N(2)–C(17), N(3)–C(21) and O(2)–C(22) are 1.225(4) Å, 1.343(4) Å, 1.456(4) Å, 1.469(4) Å and 1.404(5) Å, respectively. The torsion angles of C(22)–O(2)–C(7)=C(8), O(1)=C(1)–C(2)=C(11) and N(2)–C(19)–C(20)–N(3) are about 4.4(5)°, 1.9(5)° and 56.2(4)°, respectively. Through the Claisen–Schmidt reaction, 5-(4-methylpiperazin-1-yl)picolinaldehyde can be introduced at the C(2) position. The introduction of the double bond allows the parent nucleus and the substituent to be coplanar, with a bond length of 1.351(4) Å between C(2) and C(11). The dihedral angle between the N-methylpiperazine ring and the pyridine ring is about 7.71(3)°. Furthermore, the N-methylpiperazine ring displays “chair” conformation. 10 , 11 , 12 , 13

Corresponding author: Feng Zhao, School of Pharmacy, Binzhou Medical University, Yantai, 264003, P.R. China, E-mail:

Acknowledgments

This work was supported by Shandong Provincial Natural Science Foundation (Nos. ZR2022MH159 and ZR2023MH190) and Shandong Province Science and Technology-based Small and Medium-sized Enterprises Innovation Capacity Enhancement Project (No. 2023TSGC0870).

References

1. Rigaku, O. D. CrysAlisPRO; Rigaku Oxford Diffraction Ltd: Yarnton, Oxfordshire, England, 2017.Search in Google Scholar

2. Sheldrick, G. M. A Short History of Shelx. Acta Crystallogr. 2008, A64, 112–122; https://doi.org/10.1107/s0108767307043930.Search in Google Scholar PubMed

3. Sheldrick, G. M. Crystal Structure Refinement with Shelxl. Acta Crystallogr. 2015, C71, 3–8; https://doi.org/10.1107/s2053229614024218.Search in Google Scholar

4. Chen, Y.; Wang, J. P.; Wang, M. D.; Yu, W. X.; Cui, Y. T.; Gao, H. X.; Hou, G. G.; Ren, Y. Crystal Structure of (E)-2-(4-(1H-Imidazol-1-yl)benzylidene)-7-fluoro-3,4-dihydronaphthalen-1 (2H)-one, C20H15FN2O. Z. Kristallogr. N. Cryst. Struct. 2025, 240, 19–21; https://doi.org/10.1515/ncrs-2024-0294.Search in Google Scholar

5. Sun, Y.; Zhou, Y. Q.; Liu, Y. K.; Zhang, H. Q.; Hou, G. G.; Meng, Q. G.; Hou, Y. Potential Anti-Neuroinflammatory NF-κB Inhibitors Based on 3,4-Dihydronaphthalen-1(2H)-One Derivatives. J. Enzym. Inhib. Med. Chem. 2020, 35, 1631–1640; https://doi.org/10.1080/14756366.2020.1804899.Search in Google Scholar PubMed PubMed Central

6. Sun, Y.; Gao, Z. F.; Wang, C. H.; Hou, G. G. Synthesis, Crystal Structures and Anti-inflammatory Activity of Fluorine-Substituted 1,4,5,6-Tetrahydrobenzo [H] Quinazolin-2-Amine Derivatives. Acta. Crystallogr. C 2019, 75 (8), 1157–1165; https://doi.org/10.1107/s2053229619010118.Search in Google Scholar

7. Balamurugan, K.; Poria, D. K.; Sehareen, S. W.; Krishnamurthy, S.; Tang, W.; McKennett, L.; Padmanaban, V.; Czarra, K.; Ewald, A. J.; Ueno, N. T.; Ambs, S.; Sharan, S.; Sterneck, E. Stabilization of E-cadherin Adhesions by COX-2/GSK3β Signaling is a Targetable Pathway in Metastatic Breast Cancer. JCI Insight 2023, 8 (6), e156057; https://doi.org/10.1172/jci.insight.156057.Search in Google Scholar PubMed PubMed Central

8. Li, W. X.; Yu, L.; Chi, J. B.; Wang, J. P.; Liu, Y. J.; Wang, C. H.; Zhang, M.; Hou, G. G. Discovery of Anti-Inflammatory Agents from 3,4-Dihydronaphthalene-1(2H)-One Derivatives by Inhibiting NLRP3 Inflammasome Activation. Eur. J. Med. Chem. 2024, 268, 116284; https://doi.org/10.1016/j.ejmech.2024.116284.Search in Google Scholar PubMed

9. Mo, M.; Zeng, Y.; Zeng, Y. Q.; Li, S. T.; He, X. Y.; Chen, X. W.; Luo, Q. M.; Liu, M.; Luo, G. W.; Dou, X. R.; Peng, F. F.; Long, H. B. N-Methylpiperazine-Diepoxyovatodiolide Ameliorates Peritoneal Fibrosis via Suppressing TGF-β/Smad and JAK/STAT Signaling Pathway. Chem.–Biol. Interact. 2023, 382, 110589; https://doi.org/10.1016/j.cbi.2023.110589.Search in Google Scholar PubMed

10. Yu, L.; Wang, J.-P.; Wang, M.-D.; Yu, W.-X.; Cui, Y.-T.; Gao, H.-X.; Liu, Y.-J.; Hou, G.-G. Crystal Structure of (E)-6-(4-Ethylpiperazin-1-yl)-2-(3-Fluorobenzylidene)-3,4-Dihydronaphthalen-1(H)-One, C23H25FN2O. Z. Kristallogr. N. Cryst. Struct. 2024, 239, 515–517; https://doi.org/10.1515/ncrs-2024-0066.Search in Google Scholar

11. Qi, Q. B.; Li, W. X.; Hou, G. G.; Li, C. B. Crystal Structure of (E)-7-Bromo-2-(4-(4-methylpiperazin-1-yl)benzylidene)-3,4-dihydronaphthalen-1 (2H)-one, C22H23BrN2O. Z. Kristallogr. N. Cryst. Struct. 2023, 238 (2), 235–237; https://doi.org/10.1515/ncrs-2022-0590.Search in Google Scholar

12. Luo, H. L.; Li, W. X.; Bai, X. Y.; Meng, Q. G.; Hou, Y. Crystal Structure of (E)-7-Fluoro-2-(4-morpholinobenzylidene)-3,4-dihydronaphthalen-1(2H)-one, C21H20FNO2. Z. Kristallogr. N. Cryst. Struct. 2023, 238 (3), 495–497; https://doi.org/10.1515/ncrs-2023-0053.Search in Google Scholar

13. Xia, D.-L.; Wang, J. P.; Yu, W. X.; Wang, M. D.; Gao, H. X.; Cui, Y. T.; Hou, G. G. Crystal Structure of (E)-6,8-Dimethoxy-4-(4-morpholinobenzylidene)-3,4-dihydro-1-benzoxepin-5(2H)-one, C23H25NO5. Z. Kristallogr. N. Cryst. Struct. 2024, 239, 1133–1136; https://doi.org/10.1515/ncrs-2024-0329.Search in Google Scholar
Received: 2025-06-04
Accepted: 2025-07-16
Published Online: 2025-07-31
Published in Print: 2025-10-27

© 2025 the author(s), published by De Gruyter, Berlin/Boston

This work is licensed under the Creative Commons Attribution 4.0 International License.

Articles in the same Issue

  1. Frontmatter
  2. New Crystal Structures
  3. Crystal structure of (S)-N-(10-((2,2-dimethoxyethyl)amino)-1,2,3-trimethoxy-9-oxo-5,6,7,9-tetrahydrobenzo[a]heptalen-7-yl)acetamide, C25H32N2O7
  4. The crystal structure of 6,6′-difluoro-3,3′-dimethyl-5,5′-di(10H-phenoxazin-10-yl)- [1,1′-biphenyl]-2,2′-dicarbonitrile, C40H24F2N4O2
  5. Crystal structure of poly[(di-ethylenediamine-κ2N,N′)cadmium(II) tetradedocyloxidohexavanadate] (V4+/V5+ = 2/1), C4H16CdN4O14V6
  6. The crystal structure of poly[bis(dimethylformamide-κ1N)-(μ4-2′,3,3″,5′-tetrakis(trifluoromethyl)-[1,1′:4′,1″-terphenyl]-4,4″-dicarboxylato-κ4 O,O′: O″,O‴)dicadmium(II)], C27H15CdF12NO5
  7. Crystal structure of bis(μ2-ferrocenylcarboxylato-O,O′)-(μ3-oxido-κ3O:O:O)-bis(μ2-salicyladoximato-κ2N,O,O′)-(μ2-isopropoxo)-tris(isopropoxy-κ1O trititanium(IV)), C48H55N2O13Fe2Ti3
  8. Crystal structure of 3-(diethylamino)-7,9,11-trimethyl-8-phenyl-6H,13H-12λ4,13λ4-chromeno[3′,4′:4,5]pyrrolo[1,2-c]pyrrolo[2,1-f][1,3,2]diazaborinin-6-one, C28H26BF2N3O2
  9. The crystal structure of catena-poly[aqua-μ2-2-nitro-benzene-1,3-dicarboxylato-κ2O,O′)-(1,10-phenanthroline-κ2N,N′)-zinc(II)], C20H13N3O7Zn
  10. Crystal structure of poly[diaqua-{μ3-1-(3-carboxylatophenyl)-4-oxo-1,4-dihydropyridazine-3-carboxylato-κ4O,O′:O′′:O′′′′}manganese(II)] hydrate
  11. Crystal structure of N′-((1-hydroxycyclohexyl)(phenyl)methyl)-2-methoxybenzohydrazide methanol solvate, C22H28N2O4
  12. The cocrystal of caffeic acid — progesterone — water (1/2/1), C51H70O9
  13. Crystal structure of (((oxido(quinolin-6-yl)methoxy)triphenyl-λ5-stibanyl)oxy)(quinolin-7-yl)methanolate
  14. Crystal structure of [(E)-6′-(diethylamino)-2-(2-(((E)-pyren-1-ylmethylene)amino)ethyl)-4′-(2-((E)-1,3,3-trimethylindolin-2-ylidene)ethylidene)-1′,2′,3′,4′-tetrahydrospiro[isoindoline-1,9′-xanthen]-3-one]-methanol, solvate C57H56N4O3
  15. The crystal structure of 1-(acridin-9-yl)pyrrolidine-2,5-dione, C17H22N2O2
  16. Crystal structure of N-(4-acetylphenyl)-2-(6-methoxynaphthalen-2-yl)propanamide, C22H21NO3
  17. The crystal structure of 5,10,15,20-tetrakis(4-(1H-1,2,4-triazol-1-yl)phenyl)porphyrin, C52H34N16
  18. Crystal structure of hexacarbonyl-μ2-[phenylmethanedithiolato-κ4S:S,S′:S′]diiron (Fe–Fe) C13H6Fe2O6S2
  19. Crystal structure of diiodo-bis(1-((2-propyl-1H-benzo[d]imidazol-1-yl)methyl)-1H-benzo[d][1,2,3]triazole-κ1N)cadmium(II), C34H34CdI2N10
  20. Crystal structure of (E)-(3-(3-bromophenyl)acryloyl)ferrocene, C19H15BrFeO
  21. Crystal structure of catena-poly(μ2-6-chloropyridine-2-carboxylato-κ3N,O:O′)(6-chloropyridine-2-carboxylato-κ2O,N)copper(II), C12H6Cl2N2O4Cu
  22. Crystal structure of poly[diaqua-μ3-(5-(3,5-dicarboxy-2,4,6-trimethylbenzyl)-2,4,6-trimethylisophthalato)-κ6O,O′:O″,O‴:O‴′,O‴″) terbium(III)-monohydrate], C23H28TbO12
  23. Crystal structure of (E)-2-(((5-chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene)amino)-3′,6′-dihydroxyspiro[isoindoline-1,9′-xanthen]-3-one – ethanol (1/2), C35H33ClN4O6
  24. The crystal structure of 3-(5-amino-3-phenylisoxazol-4-yl)-4-chloro-3-hydroxyindolin-2-one, C17H12ClN3O3
  25. The crystal structure of dimethylammonium 4-[2-(4-fluorophenyl)-4, 5-diphenyl-1H-imidazol-1-yl]benzenesulfonate, C29H26FN3O3S
  26. Crystal structure of (R)-2-ammonio-3-((5-carboxypentyl)thio)propanoate
  27. Crystal structure of 4-cyclohexyl-5-(thiophen-2-yl)-2,4-dihydro-3H-1,2,4-triazole-3-thione, C12H15N3S2
  28. The crystal structure of 4,6-bis(dimethylamino)-2-fluoroisophthalonitrile, C12H13FN4
  29. Hydrogen bonding in the crystal structure of nicotin-1,1′-dium tetrabromidomanganate(II)
  30. The crystal structure of bis(2-bromobenzyl)(2-((2-oxybenzylidene)amino)-4-methylpentanoato-κ3N, O,O′)tin(IV), C27H27Br2NO3Sn
  31. Crystal structure of (E)-(3-(p-tolyl)acryloyl)ferrocene, C20H18FeO
  32. Crystal structure of (E)-7-fluoro-2-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)methylene)-3,4-dihydronaphthalen-1(2H)-one, C21H22FN3O
  33. Crystal structure of (E)-7-methoxy-2-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)methylene)-3,4-dihydronaphthalen-1(2H)-one, C22H25N3O2
  34. The crystal structure of poly(bis(μ2-1,3,5-tri(1H-imidazol-1-yl)benzene-κ2N:N′)-(μ2-2,3,5,6-tetrafluoroterephthalato-κ2O:O′)-manganese(II), C38H24F4N12O4Mn
  35. Crystal structure of (3,4-dimethoxybenzyl)triphenylphosphonium bromide ethanol solvate, C29H32BrO3P
  36. Crystal structure of tetraethylammonium hydrogencarbonate – (diaminomethylene)thiourea – water (2/1/3)
  37. Crystal structure of N, N-Dimethyl-N′-tosylformimidamide, C10H14N2O2S
  38. The crystal structure of ethyl 2-methyl-5-oxo-4-(2-methoxyphenyl)-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate, C20H23N2O4
  39. Crystal structure of bis(μ2-1,5-bis[(E)-1-(2-hydroxyphenyl)ethylidene] thiocarbonohydrazide)-bis(dimethylformamide)-dizinc(II) dimethylformamide solvate, C40H46N10O6S2Zn2⋅C3H7NO
  40. Crystal structure of azido-κ1N{hydridotris(3-tert-butyl-5-methylpyrazol-1-yl)borato-κ3N,N′,N″}copper(II), C24H40BCuN9
  41. The crystal structure of fac-tricarbonyl(1,10-phenanthroline-κ2N,N′)-(azido-κ1N)rhenium(I), C15H8N5O3Re
  42. Crystal structure of 4-((triphenylphosphonio)methyl)pyridin-1-ium tetrachloridozincate(II), C24H22Cl4NPZn
https://doi.org/10.1515/ncrs-2025-0261
Creative Commons
BY 4.0

Articles in the same Issue

  1. Frontmatter
  2. New Crystal Structures
  3. Crystal structure of (S)-N-(10-((2,2-dimethoxyethyl)amino)-1,2,3-trimethoxy-9-oxo-5,6,7,9-tetrahydrobenzo[a]heptalen-7-yl)acetamide, C25H32N2O7
  4. The crystal structure of 6,6′-difluoro-3,3′-dimethyl-5,5′-di(10H-phenoxazin-10-yl)- [1,1′-biphenyl]-2,2′-dicarbonitrile, C40H24F2N4O2
  5. Crystal structure of poly[(di-ethylenediamine-κ2N,N′)cadmium(II) tetradedocyloxidohexavanadate] (V4+/V5+ = 2/1), C4H16CdN4O14V6
  6. The crystal structure of poly[bis(dimethylformamide-κ1N)-(μ4-2′,3,3″,5′-tetrakis(trifluoromethyl)-[1,1′:4′,1″-terphenyl]-4,4″-dicarboxylato-κ4 O,O′: O″,O‴)dicadmium(II)], C27H15CdF12NO5
  7. Crystal structure of bis(μ2-ferrocenylcarboxylato-O,O′)-(μ3-oxido-κ3O:O:O)-bis(μ2-salicyladoximato-κ2N,O,O′)-(μ2-isopropoxo)-tris(isopropoxy-κ1O trititanium(IV)), C48H55N2O13Fe2Ti3
  8. Crystal structure of 3-(diethylamino)-7,9,11-trimethyl-8-phenyl-6H,13H-12λ4,13λ4-chromeno[3′,4′:4,5]pyrrolo[1,2-c]pyrrolo[2,1-f][1,3,2]diazaborinin-6-one, C28H26BF2N3O2
  9. The crystal structure of catena-poly[aqua-μ2-2-nitro-benzene-1,3-dicarboxylato-κ2O,O′)-(1,10-phenanthroline-κ2N,N′)-zinc(II)], C20H13N3O7Zn
  10. Crystal structure of poly[diaqua-{μ3-1-(3-carboxylatophenyl)-4-oxo-1,4-dihydropyridazine-3-carboxylato-κ4O,O′:O′′:O′′′′}manganese(II)] hydrate
  11. Crystal structure of N′-((1-hydroxycyclohexyl)(phenyl)methyl)-2-methoxybenzohydrazide methanol solvate, C22H28N2O4
  12. The cocrystal of caffeic acid — progesterone — water (1/2/1), C51H70O9
  13. Crystal structure of (((oxido(quinolin-6-yl)methoxy)triphenyl-λ5-stibanyl)oxy)(quinolin-7-yl)methanolate
  14. Crystal structure of [(E)-6′-(diethylamino)-2-(2-(((E)-pyren-1-ylmethylene)amino)ethyl)-4′-(2-((E)-1,3,3-trimethylindolin-2-ylidene)ethylidene)-1′,2′,3′,4′-tetrahydrospiro[isoindoline-1,9′-xanthen]-3-one]-methanol, solvate C57H56N4O3
  15. The crystal structure of 1-(acridin-9-yl)pyrrolidine-2,5-dione, C17H22N2O2
  16. Crystal structure of N-(4-acetylphenyl)-2-(6-methoxynaphthalen-2-yl)propanamide, C22H21NO3
  17. The crystal structure of 5,10,15,20-tetrakis(4-(1H-1,2,4-triazol-1-yl)phenyl)porphyrin, C52H34N16
  18. Crystal structure of hexacarbonyl-μ2-[phenylmethanedithiolato-κ4S:S,S′:S′]diiron (Fe–Fe) C13H6Fe2O6S2
  19. Crystal structure of diiodo-bis(1-((2-propyl-1H-benzo[d]imidazol-1-yl)methyl)-1H-benzo[d][1,2,3]triazole-κ1N)cadmium(II), C34H34CdI2N10
  20. Crystal structure of (E)-(3-(3-bromophenyl)acryloyl)ferrocene, C19H15BrFeO
  21. Crystal structure of catena-poly(μ2-6-chloropyridine-2-carboxylato-κ3N,O:O′)(6-chloropyridine-2-carboxylato-κ2O,N)copper(II), C12H6Cl2N2O4Cu
  22. Crystal structure of poly[diaqua-μ3-(5-(3,5-dicarboxy-2,4,6-trimethylbenzyl)-2,4,6-trimethylisophthalato)-κ6O,O′:O″,O‴:O‴′,O‴″) terbium(III)-monohydrate], C23H28TbO12
  23. Crystal structure of (E)-2-(((5-chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene)amino)-3′,6′-dihydroxyspiro[isoindoline-1,9′-xanthen]-3-one – ethanol (1/2), C35H33ClN4O6
  24. The crystal structure of 3-(5-amino-3-phenylisoxazol-4-yl)-4-chloro-3-hydroxyindolin-2-one, C17H12ClN3O3
  25. The crystal structure of dimethylammonium 4-[2-(4-fluorophenyl)-4, 5-diphenyl-1H-imidazol-1-yl]benzenesulfonate, C29H26FN3O3S
  26. Crystal structure of (R)-2-ammonio-3-((5-carboxypentyl)thio)propanoate
  27. Crystal structure of 4-cyclohexyl-5-(thiophen-2-yl)-2,4-dihydro-3H-1,2,4-triazole-3-thione, C12H15N3S2
  28. The crystal structure of 4,6-bis(dimethylamino)-2-fluoroisophthalonitrile, C12H13FN4
  29. Hydrogen bonding in the crystal structure of nicotin-1,1′-dium tetrabromidomanganate(II)
  30. The crystal structure of bis(2-bromobenzyl)(2-((2-oxybenzylidene)amino)-4-methylpentanoato-κ3N, O,O′)tin(IV), C27H27Br2NO3Sn
  31. Crystal structure of (E)-(3-(p-tolyl)acryloyl)ferrocene, C20H18FeO
  32. Crystal structure of (E)-7-fluoro-2-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)methylene)-3,4-dihydronaphthalen-1(2H)-one, C21H22FN3O
  33. Crystal structure of (E)-7-methoxy-2-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)methylene)-3,4-dihydronaphthalen-1(2H)-one, C22H25N3O2
  34. The crystal structure of poly(bis(μ2-1,3,5-tri(1H-imidazol-1-yl)benzene-κ2N:N′)-(μ2-2,3,5,6-tetrafluoroterephthalato-κ2O:O′)-manganese(II), C38H24F4N12O4Mn
  35. Crystal structure of (3,4-dimethoxybenzyl)triphenylphosphonium bromide ethanol solvate, C29H32BrO3P
  36. Crystal structure of tetraethylammonium hydrogencarbonate – (diaminomethylene)thiourea – water (2/1/3)
  37. Crystal structure of N, N-Dimethyl-N′-tosylformimidamide, C10H14N2O2S
  38. The crystal structure of ethyl 2-methyl-5-oxo-4-(2-methoxyphenyl)-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate, C20H23N2O4
  39. Crystal structure of bis(μ2-1,5-bis[(E)-1-(2-hydroxyphenyl)ethylidene] thiocarbonohydrazide)-bis(dimethylformamide)-dizinc(II) dimethylformamide solvate, C40H46N10O6S2Zn2⋅C3H7NO
  40. Crystal structure of azido-κ1N{hydridotris(3-tert-butyl-5-methylpyrazol-1-yl)borato-κ3N,N′,N″}copper(II), C24H40BCuN9
  41. The crystal structure of fac-tricarbonyl(1,10-phenanthroline-κ2N,N′)-(azido-κ1N)rhenium(I), C15H8N5O3Re
  42. Crystal structure of 4-((triphenylphosphonio)methyl)pyridin-1-ium tetrachloridozincate(II), C24H22Cl4NPZn
Sign up now to receive a 20% welcome discount
Institutional Access
How does access work?
Have an idea on how to improve our website?
Please write us.
© 2025 De Gruyter Brill
Downloaded on 9.10.2025 from https://www.degruyterbrill.com/document/doi/10.1515/ncrs-2025-0261/html?recommended=sidebar
Scroll to top button